Surgical · Other

Surgical removal of a noncancerous tumor or cyst from the upper jaw (maxilla) or cheekbone (zygoma) using enucleation, curettage, or both techniques.

Verified May 8, 2026 · 6 sources ↓

Medicare: $475.96
Total RVUs: 14.25
Global, days: 90
Region: Other

Drawn from CMSMdclarityAAPCNIH

Documentation requirements

What must appear in the operative or office note to support the claim.

Source · Editorial brief grounded in 6 cited references ↓

Pathology or imaging confirming benign nature of the lesion prior to excision
Operative note specifying the technique used — enucleation, curettage, or combined — and confirming complete removal
Exact anatomic site documented: maxilla (upper jaw) vs. zygoma (cheekbone), and laterality (left, right, or bilateral)
Lesion size and any factors supporting increased procedural complexity if modifier 22 is appended
Anesthesia type and any assistant surgeon role documented if modifier AS is used
Pathology report confirming benign diagnosis to support medical necessity post-procedure

Applicable modifiers

Modifiers commonly billed with this code.

Source · AMA CPT modifier descriptors · CMS NCCI Policy Manual

22 Increased complexity 50 Bilateral procedure 51 Multiple procedures 52 Reduced services 58 Staged or related 62 Co-surgeons 78 Unplanned return — related 79 Unrelated during global 80 Assistant surgeon AS PA/NP/CNS assistant LT Left side RT Right side

What this code covers

Source · Editorial summary grounded in 6 cited references ↓

CPT 21030 covers excision of a benign tumor or cyst from the maxilla or zygoma through enucleation — removal of the lesion as a single intact mass — followed by curettage, in which a curette scrapes the surrounding bone to clear residual abnormal tissue. The procedure requires an incision over the affected site, careful dissection to isolate the lesion, and closure with sutures. Local or general anesthesia may be used depending on lesion size and patient factors.

This code carries a 90-day global period, meaning all routine postoperative care through day 90 is bundled into the surgical payment. Any unrelated E/M visit during that window requires modifier 24; a significant, separately identifiable E/M on the day of surgery requires modifier 25. Debridement within the surgical field is not separately reportable per NCCI policy — do not stack a debridement code on top of 21030.

The procedure is billed predominantly by oral and maxillofacial surgeons. Laterality matters for facility billing: in the ASC setting, report bilateral cases on two separate claim lines with modifiers LT and RT rather than modifier 50 alone, consistent with CMS NCCI 2026 guidance. The dramatic spread between HOPD and ASC facility payments for this code makes site-of-service selection a significant revenue consideration.

RVU & reimbursement

Component RVUs and Medicare national rate. Actual payment varies by GPCI locality.

Source · CMS Physician Fee Schedule, RVU26A · January 2026

Work RVU	4.79
Practice expense RVU	8.87
Malpractice RVU	0.59
Total RVU	14.25
Medicare national rate	$475.96
Global period	90 days

Payment by site of service

Medicare pays different rates by setting. HOPD typically pays substantially more than ASC for the same procedure.

Source · CMS OPPS Addendum B·ASC HCPCS payment rates·2026

Setting	Medicare rate (national)
Office (PFS non-facility) Procedure performed in physician's office	$475.96
HOPD (APC 5165) Hospital outpatient department	$6,048.05
ASC (PI P3) Ambulatory surgical center (freestanding)	$297.74

Common denial reasons

The recurring reasons claims for CPT 21030 get rejected.

Source · Editorial brief grounded in CMS NCCI edits, AAOS coding appeals, and cited references ↓

Laterality not specified in the claim or operative report, triggering a claim edit or payer rejection
Malignant lesion documented in pathology but 21030 (benign) was billed — code should be 21034 for malignant excision
Debridement code billed separately when performed within the same surgical field, creating an NCCI bundling conflict
Modifier 22 appended without supporting documentation of what made the procedure significantly more complex than typical
Global period violation — postoperative E/M billed without modifier 24 when the visit was within the 90-day global window

Frequently asked questions

Source · Generated from the editorial pipeline, verified against 6 cited references ↓

01What is the difference between CPT 21030 and CPT 21034?

21030 is for benign tumors or cysts of the maxilla or zygoma. 21034 covers malignant tumors of the same bones. Pathology confirmation drives the correct code — billing 21030 when pathology returns malignant is a guaranteed denial or take-back.

02How do you bill 21030 for a bilateral procedure?

In the physician office setting, append modifier 50. In the ASC, CMS requires two separate claim lines — one with modifier LT and one with modifier RT — each with one unit of service. Do not use modifier 50 alone for ASC facility billing.

03Can you bill a separate debridement code with 21030?

No. Per CMS NCCI 2026 policy, debridement of tissue within the surgical field of a musculoskeletal excision procedure is not separately reportable. Curettage of the surrounding bone is already inherent to the 21030 descriptor.

04When is modifier 22 appropriate with 21030?

Append modifier 22 when documented factors — such as unusual lesion size, difficult anatomic location, extensive adhesions, or prior surgery in the field — caused the procedure to require substantially greater work than typical. The operative note must spell out what made it harder; a generic statement will not hold up on audit.

05Does the 90-day global period affect E/M billing after 21030?

Yes. All routine postoperative E/M visits within 90 days of surgery are bundled and not separately billable. If you see the patient for an unrelated problem during that window, append modifier 24 to the E/M. A significant, separately identifiable E/M on the day of surgery needs modifier 25.

06Who typically bills CPT 21030?

Oral surgeons (dentist-only credential) and maxillofacial surgeons account for the vast majority of 21030 claims per CMS Physician Utilization and Payment File data. General surgeons and ENT surgeons bill it occasionally when they perform facial bone excisions.

Sources & references

Editorial content was developed using the following public sources. Last verified May 8, 2026.

Mira AI Scribe

Mira's AI scribe captures the surgical approach, lesion location (maxilla vs. zygoma), laterality, technique (enucleation and/or curettage), estimated lesion size, and any factors adding procedural complexity — all from dictation. This prevents the two most common 21030 denials: missing laterality and unsupported modifier 22 claims.

See how Mira captures CPT 21030 documentation